Orphazyme CFO on failed trial: "Highly disappointing and highly surprising"

Monday's announcement that Orphazyme's main candidate, arimoclomol, for treating degenerative muscle disease IBM has not met its effect targets is highly disappointing and surprising, says the firm's CFO. Now, the company considers scaling back its efforts in the area.

Orpazyme CFO and interim CEO Anders Vadsholt. | Photo: Orphazyme / PR

"This is highly disappointing and and highly surprising."

So stated Orphazyme's Chief Financial Officer and interim CEO Anders Vadsholt following the company's Monday announcement that the phase II/III trial involving its main candidate, arimoclomol, as a treatment for the degenerative muscle disease inclusion body myositis (IBM) has not met its effect targets.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs